Minimal Change Disease

The contract between this chapter and the reader.

1. 1. Define minimal change disease and its podocyte mechanism.
2. 2. Recognise its clinical presentation.
3. 3. Diagnose it, including when to biopsy.
4. 4. Describe the biopsy (light, immunofluorescence, electron).
5. 5. Treat with corticosteroids.
6. 6. Manage relapse and steroid dependence.
7. 7. Use steroid-sparing agents appropriately.
8. 8. Provide supportive care for the nephrotic state.
9. 9. Distinguish minimal change disease from FSGS.

A sixty-second reading. Each bullet stands alone.

• Minimal change disease is the commonest cause of nephrotic syndrome in children.
• It is a podocytopathy: diffuse foot-process effacement with minimal light-microscopy change and negative immunofluorescence.
• It is presumed immune-mediated, from a circulating permeability factor or T-cell dysregulation.
• It presents as an abrupt nephrotic syndrome with marked edema and a bland sediment.
• In children with a classic presentation, it is treated empirically with steroids without biopsy.
• In adults it is biopsied, showing the electron-microscopy-only changes.
• It is highly steroid-responsive — most patients remit.
• Relapse is common; patients may be relapsing, frequently relapsing, or steroid-dependent.
• Steroid-sparing agents (calcineurin inhibitors, cyclophosphamide, rituximab, mycophenolate) are used for frequent relapse or steroid dependence.
• Supportive care addresses edema, thrombosis risk, and hyperlipidemia.
• The long-term prognosis is excellent and progression to kidney failure is rare.
• It is distinguished from FSGS, which is often steroid-resistant and can progress.
• The steroid response itself carries diagnostic information.

The medical core. An expert should agree minimal change disease is fully covered here.

Why it matters at the bedside

Minimal change disease is the friendliest of the glomerular diseases: it floods the body with protein, yet under the light microscope the glomerulus looks almost normal, and a course of steroids usually melts the proteinuria away. The lessons it teaches — that the diagnosis can live entirely in the electron microscope, and that the response to treatment is itself a clue — echo through the whole nephrotic story.

What it is and its mechanism

• Minimal change disease is the commonest cause of nephrotic syndrome in children (and an important one in adults). It is a pure podocytopathy: the only consistent abnormality is diffuse effacement of the podocyte foot processes on electron microscopy, with ‘minimal’ change on light microscopy and negative immunofluorescence. The injury is presumed immune-mediated — a circulating permeability factor and T-cell dysregulation altering the slit diaphragm — and is usually idiopathic, though it can be secondary to NSAIDs, Hodgkin lymphoma, or allergy.

Clinical presentation

• It presents abruptly with the full nephrotic syndrome: heavy, albumin-selective proteinuria, hypoalbuminemia, often striking oedema, and hyperlipidemia, with a bland urinary sediment. Kidney function and blood pressure are usually normal (though acute kidney injury can occur), and the complications are those of the nephrotic state — a thrombosis-prone, infection-prone condition.

Diagnosis and when to biopsy

• Diagnosis turns on age. In a child with a classic nephrotic presentation, minimal change is so likely that treatment with steroids begins empirically, biopsy being reserved for atypical features or steroid resistance. In adults, the nephrotic syndrome is biopsied — to confirm minimal change and exclude FSGS and other causes — and the response to steroids then adds further diagnostic information.

The biopsy

• The biopsy is the archetypal electron-microscopy diagnosis (the biopsy chapter): light microscopy is normal or near-normal, immunofluorescence is negative, and only electron microscopy reveals the diffuse foot-process effacement. It is the clearest demonstration of why all three microscopies are needed and why electron microscopy is indispensable in nephrotic disease.

Corticosteroid treatment

• Corticosteroids are the first-line treatment and the disease's defining feature: minimal change is highly steroid-responsive, and most patients achieve remission. The steroid response is so characteristic that it is itself diagnostic — a steroid-responsive nephrotic syndrome behaves like minimal change, while steroid resistance points elsewhere (typically FSGS).

Relapse and steroid dependence

• The catch is relapse, which is common. Patients are categorised by their pattern: infrequently relapsing, frequently relapsing, or steroid-dependent (relapsing as steroids are tapered or stopped). Frequent relapse and steroid dependence are the problem to solve, because repeated or continuous steroid courses accumulate toxicity — which is what drives the move to steroid-sparing therapy.

Steroid-sparing agents

• For frequently relapsing or steroid-dependent disease (and for steroid resistance), a steroid-sparing agent is added to maintain remission with less steroid exposure: a calcineurin inhibitor (cyclosporine or tacrolimus), cyclophosphamide, rituximab, or mycophenolate (with levamisole an option in children). The choice balances efficacy against each agent's toxicity, the same logic met throughout the transplant volume.

Supportive care

• Alongside immunosuppression, the nephrotic state is managed supportively: oedema with salt restriction and diuretics, the hypercoagulable thrombosis risk with prophylaxis where appropriate, and hyperlipidemia with a statin — the supportive backbone common to all nephrotic disease (the supportive-therapy chapter).

Prognosis

• The prognosis is excellent: minimal change rarely progresses to kidney failure — unlike FSGS — and long-term kidney function is preserved. Relapses are common but manageable, and even steroid-dependent patients generally do well on steroid-sparing regimens. The reassurance is real, and it is one of the chapter's key counselling points.

MCD versus FSGS

• The crucial differential is FSGS, with which minimal change shares a spectrum. Minimal change has normal light microscopy, is steroid-responsive, and does not usually progress; FSGS shows segmental sclerosis, is often steroid-resistant, and can progress to end-stage disease. Because FSGS is focal, a small biopsy can miss the sclerosis and mimic minimal change — so steroid resistance in apparent ‘minimal change’ should prompt reconsideration of FSGS.

Five fully-built tables.

Table A — The disease at a glance

Table B — Presentation and diagnosis

Table C — Treatment and relapse categories

Table D — Steroid-sparing agents

Table E — MCD versus FSGS

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — The leaking podocyte

A permeability factor / T-cell dysregulation → podocyte injury → foot-process effacement → massive selective proteinuria → ACTION: treat with corticosteroids.

Chain 2 — The invisible lesion

‘Minimal’ light microscopy and negative immunofluorescence, but effacement on electron microscopy → the abnormality is ultrastructural → ACTION: perform electron microscopy to make the diagnosis.

Chain 3 — The steroid signature

Minimal change is a steroid-responsive podocytopathy → most patients remit on steroids → the response is itself diagnostic → ACTION: use corticosteroids first-line and read the response.

Chain 4 — The relapse toll

Frequent relapse / steroid dependence → repeated or continuous steroid exposure → cumulative steroid toxicity → ACTION: add a steroid-sparing agent.

Chain 5 — No scar, no progression

Minimal change has no glomerulosclerosis → the kidney is not scarred → it rarely progresses (unlike FSGS) → ACTION: reassure, and reconsider FSGS if the course is atypical.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Minimal change diagnosis / treatment note

• Presentation: nephrotic syndrome; age (child/adult); sediment ___.
• Diagnosis: empiric (child) / biopsy (EM foot-process effacement) ___.
• Secondary causes considered (NSAIDs, lymphoma): ___.
• Treatment: corticosteroids; supportive (edema, thrombosis, statin) ___.
• Response and plan: ___.

Template 2 — Relapse / steroid-sparing note

• Course: relapsing / frequently relapsing / steroid-dependent / steroid-resistant.
• Steroid toxicity / cumulative exposure: ___.
• Steroid-sparing agent chosen and rationale: ___.
• If steroid-resistant: FSGS reconsidered; CNI: ___.
• Monitoring (proteinuria, toxicity): ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Nine items, each anchored in this chapter. At least one per objective.